Skip to content

10-year follow-up after sacrocolpopexy for surgical treatment of vaginal vault prolapse POP-Q II-III

10-year follow-up after sacrocolpopexy for surgical treatment of vaginal vault prolapse POP-Q II-III

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00028590
Enrollment
208
Registered
2022-03-21
Start date
2022-03-25
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N99.3

Interventions

Group 1: The 10-year ± months follow-up examination comprises: a gynecological examination with determination of the POP-Q stage classification and the notification of penetration of suture material i

Sponsors

Universitäts-Frauenklinik Tübingen
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 95 Years

Inclusion criteria

Inclusion criteria: All patients who participated in the previous study: “Absorbable versus non-absorbable sutures for vaginal mesh attachment during sacrocolpopexy for surgical treatment of vaginal vault prolapse POP-Q II-III” (DRKS00003263). This is a 10-year and ±6 months follow-up examination.

Exclusion criteria

Exclusion criteria: Patients who did not participate in the previous study: “Absorbable versus non-absorbable sutures for vaginal mesh attachment during sacrocolpopexy for surgical treatment of vaginal vault prolapse POP-Q II-III” (DRKS00003263). This is a 10-year and ±6 months follow-up examination.

Design outcomes

Primary

MeasureTime frame
The primary objective is to evaluate the anatomical outcome. Success was defined when the vaginal apex (point C; POPQ) did not descend more than 50% of the total vaginal length during Valsalva.

Secondary

MeasureTime frame
The secondary objectives comprises functional parameters and symptomatic/ asymptomatic penetration of the suture material into the vagina. The German pelvic floor questionnaire is used to evaluate prolapse, urinary and bowel symptoms, and sexual function. The PISQ-12 questionnaire is additionally administered to evaluate sexual function.

Countries

Germany

Contacts

Public ContactChristl Reisenauer

Universitäts-Frauenklinik Tübingen

christl.reisenauer@med.uni-tuebingen.de070712986211

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026